Spimaco aligns Qassim subscription with advisor

The article discussed developments related to Qassim Medical Services Company's planned offering in the parallel market "Nomu." The company is majority-owned at 57.23% by Spimaco Pharmaceutical Company. The evaluation of the offering structure remains ongoing between direct sale of a portion of shares and a capital increase involving new investors, with the final decision depending on the results of financial studies and the ultimate valuation. It is expected that the listing will enhance the company's investment value, support future growth, improve governance and transparency levels, and expand the investor base. Additionally, it was noted that the company has experienced improvements in revenues and financial performance over the past three years. The company is also considering the potential use of proceeds from the offering to reduce debt, fund new pharmaceutical investments, or return some value to shareholders. The process depends on the speed of completing procedures and achieving alignment with market conditions, with a focus on boosting local content and the localization of biotechnology and advanced treatments within the Kingdom.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل